Summary
21.68 -0.97(-4.28%)12/12/2025
Forte Biosciences, Inc. (FBRX)
FBRX reported last earnings on 2025-11-14 after the market. An EPS of $-0.99 was observed compared to an estimated EPS of $-1.04, resulting in a surprise value of $0.05. A revenue of $0 million was observed compared to an estimated revenue of $0 million, resulting in a surprise value of $0 Million.
Forte Biosciences, Inc. (FBRX)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years |
| -4.28 | 6.84 | 53.77 | 76.59 | 73.37 | 24.32 | -97.91 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan!
Fundamental Ratings
| Category | Rating |
| Main Rating | C- |
| Recommended Rating | Strong Sell |
| DCF | Neutral |
| ROE | Strong Sell |
| ROA | Strong Sell |
| Debt/Equity | Strong Sell |
| P/E | Strong Sell |
| P/B | Sell |
Earnings
| Trading Data | ||
| Close | 21.68 | |
| Open | 22.68 | |
| High | 23.71 | |
| Low | 21.41 | |
| Volume | 203,177 | |
| Change | -0.97 | |
| Change % | -4.28 | |
| Avg Volume (20 Days) | 113,319 | |
| Volume/Avg Volume (20 Days) Ratio | 1.79 | |
| 52 Week Range | 5.42 - 28.68 | |
| Price vs 52 Week High | -24.40% | |
| Price vs 52 Week Low | 300.03% | |
| Range | 0.00 | |
| Gap Up/Down | -0.08 | |
Profitibility | ||
| Market Capitalization (Mln) | 160 | |
| Revenue per share | 0.0021 | |
| Net Income per share | -2.9078 | |
| Dividend Yield | 0.0000 | |
| Dividend Share | 0.00% | |
Valuations | ||
| Enterprise Value | 0.00% | |
| PE Ratio | -7.7996 | |
| PB Ratio | 0.0000 | |
| PTB Ratio | 0.0000 | |
Liquidity | ||
| Debt/Equity Ratio | 0.0000 | |
| Net Debt/EBIDTA Ratio | 0.0000 | |
| Current Ratio | 0.0000 | |
Enterprise Value and Cash Flow | ||
| EV/Sales Ratio | 0.0000 | |
| EV/EBIDTA Ratio | 0.0000 | |
| EV/Free Cash Flow Ratio | 0.0000 | |
12/11 04:21 EST - defenseworld.net
Federated Hermes Inc. Buys New Shares in Forte Biosciences, Inc. $FBRX
Federated Hermes Inc. purchased a new position in shares of Forte Biosciences, Inc. (NASDAQ: FBRX) in the second quarter, according to its most recent filing with the SEC. The firm purchased 1,072,233 shares of the company's stock, valued at approximately $13,864,000. Federated Hermes Inc. owned...
Federated Hermes Inc. Buys New Shares in Forte Biosciences, Inc. $FBRX
Federated Hermes Inc. purchased a new position in shares of Forte Biosciences, Inc. (NASDAQ: FBRX) in the second quarter, according to its most recent filing with the SEC. The firm purchased 1,072,233 shares of the company's stock, valued at approximately $13,864,000. Federated Hermes Inc. owned...
11/27 02:12 EST - defenseworld.net
Forte Biosciences Target of Unusually High Options Trading (NASDAQ:FBRX)
Forte Biosciences, Inc. (NASDAQ: FBRX - Get Free Report) was the recipient of some unusual options trading on Wednesday. Stock traders purchased 30,205 call options on the company. This represents an increase of 1,663% compared to the average daily volume of 1,713 call options. Forte Biosciences...
Forte Biosciences Target of Unusually High Options Trading (NASDAQ:FBRX)
Forte Biosciences, Inc. (NASDAQ: FBRX - Get Free Report) was the recipient of some unusual options trading on Wednesday. Stock traders purchased 30,205 call options on the company. This represents an increase of 1,663% compared to the average daily volume of 1,713 call options. Forte Biosciences...
11/24 16:01 EST - businesswire.com
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related...
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related...
11/14 09:00 EST - businesswire.com
Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides Update
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its third quarter 2025 financial results and provided a business update. “We continue to make...
Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides Update
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its third quarter 2025 financial results and provided a business update. “We continue to make...
11/03 03:59 EST - defenseworld.net
Forte Biosciences, Inc. $FBRX Stake Boosted by AlphaQuest LLC
AlphaQuest LLC grew its stake in shares of Forte Biosciences, Inc. (NASDAQ: FBRX) by 300.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 16,897 shares of the company's stock after buying an additional...
Forte Biosciences, Inc. $FBRX Stake Boosted by AlphaQuest LLC
AlphaQuest LLC grew its stake in shares of Forte Biosciences, Inc. (NASDAQ: FBRX) by 300.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 16,897 shares of the company's stock after buying an additional...
10/03 16:01 EST - businesswire.com
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules. In...
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules. In...
09/15 09:00 EST - businesswire.com
Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, announced additional details from the oral presentation “FB102 prevents histological damage and mitigates gluten...
Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, announced additional details from the oral presentation “FB102 prevents histological damage and mitigates gluten...
08/14 16:01 EST - businesswire.com
Forte Biosciences, Inc. Announces Results and Provides Update
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its second quarter 2025 financial results and provided a business update. “I am deeply...
Forte Biosciences, Inc. Announces Results and Provides Update
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its second quarter 2025 financial results and provided a business update. “I am deeply...
06/25 00:28 EST - businesswire.com
Forte Biosciences Announces Pricing of $75 Million Public Offering
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the pricing of a public offering of 5,630,450 shares of its common stock at a price to the public of $12.00 per share...
Forte Biosciences Announces Pricing of $75 Million Public Offering
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the pricing of a public offering of 5,630,450 shares of its common stock at a price to the public of $12.00 per share...
06/24 16:01 EST - businesswire.com
Forte Biosciences Announces Proposed Public Offering
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to...
Forte Biosciences Announces Proposed Public Offering
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to...
06/23 07:18 EST - businesswire.com
Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced positive data from a Phase 1b trial in celiac disease for lead program FB102 (FB102-101). The...
Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced positive data from a Phase 1b trial in celiac disease for lead program FB102 (FB102-101). The...
04/03 13:05 EST - zacks.com
All You Need to Know About Forte Biosciences (FBRX) Rating Upgrade to Buy
Forte Biosciences (FBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
All You Need to Know About Forte Biosciences (FBRX) Rating Upgrade to Buy
Forte Biosciences (FBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
01/03 10:01 EST - zacks.com
Forte Biosciences (FBRX) Is a Great Choice for 'Trend' Investors, Here's Why
Forte Biosciences (FBRX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Forte Biosciences (FBRX) Is a Great Choice for 'Trend' Investors, Here's Why
Forte Biosciences (FBRX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
11/28 09:51 EST - zacks.com
Here's Why Momentum in Forte Biosciences (FBRX) Should Keep going
Forte Biosciences (FBRX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Here's Why Momentum in Forte Biosciences (FBRX) Should Keep going
Forte Biosciences (FBRX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
11/20 09:00 EST - businesswire.com
Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced an oversubscribed $53 million equity financing to support the continuing clinical advancement of...
Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced an oversubscribed $53 million equity financing to support the continuing clinical advancement of...
11/19 13:01 EST - zacks.com
Forte Biosciences (FBRX) Upgraded to Buy: What Does It Mean for the Stock?
Forte Biosciences (FBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Forte Biosciences (FBRX) Upgraded to Buy: What Does It Mean for the Stock?
Forte Biosciences (FBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
05/13 16:05 EST - businesswire.com
Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business Update
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced first quarter 2024 results and provided a business update. First Quarter 2024 Business Highlights...
Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business Update
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced first quarter 2024 results and provided a business update. First Quarter 2024 Business Highlights...
03/25 13:01 EST - zacks.com
What Makes Forte Biosciences (FBRX) a New Buy Stock
Forte Biosciences (FBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
What Makes Forte Biosciences (FBRX) a New Buy Stock
Forte Biosciences (FBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Market News
×
Loading news…